ArticleAnnals of Saudi medicine

Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients.

Ahmed Kotb Abdrabou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.